IntegraGen announces miR-31-3p publication in Oncotarget

IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…)  » 

IntegraGen Reports Revenues for First Half of 2016

IntegraGen today announced its sales for the first half 2016. Sales for IntegraGen’s business totaled € 2.8 million as of June 30, 2016, and increase of 10% compared to the first half of 2015.

Financials

Sales of € 2.8 million, a 10% increase vs. H1 2015 Operational result +14% (…)  »